Research Article

Down-regulation of microRNA-142-3p inhibits the aggressive phenotypes of rheumatoid arthritis fibroblast-like synoviocytes through inhibiting nuclear factor-κB signaling

Jianhong Qiang1, Tingting Lv2, Zhenbiao Wu3 and Xichao Yang3

1Department of Traditional Chinese Medicine, Yan’an People’s Hospital, No. 57, Qilipu Street, Baota District, Yan’an City 716000, Shaanxi Province, China; 2Department of Rheumatology and Immunology, The Second Affiliated Hospital of The Fourth Military Medical University, No. 569, Xinsi Road, Xi’an City 710038, Shaanxi Province, China; 3Department of Clinical Immunology, The First Affiliated Hospital of The Fourth Military Medical University, No. 1, Changle East Road, Xi’an City 710032, Shaanxi Province, China

Correspondence: Xichao Yang (yangxichao258@163.com)

The present study aimed to investigate the regulatory roles of miR-142-3p on the aggressive phenotypes of rheumatoid arthritis (RA) human fibroblast-like synoviocytes (RA-HFLSs), and reveal the potential mechanisms relating with nuclear factor-κB (NF-κB) signaling. miR-142-3p expression was detected in RA synovial tissues and RA-HFLSs by quantitative real-time PCR (qRT-PCR) and Northern blot analysis. RA-HFLSs were transfected with miR-142-3p inhibitor and/or treated with 10 μg/l tumor necrosis factor α (TNF-α). The viability, colony formation, apoptosis, migration, invasion, and the levels of interleukin (IL)-6, and matrix metalloproteinase 3 (MMP-3) were detected. The mRNA expressions of B-cell lymphoma-2 (Bcl-2), Bax, Bad, IL-6, and MMP-3 were detected by qRT-PCR. Moreover, the expression of Bcl-2, IL-1 receptor-associated kinase 1 (IRAK1), Toll-like receptor 4 (TLR4), NF-κB p65, and phosphorylated NF-κB p65 (p-NF-κB p65) were detected by Western blot. The interaction between IRAK1 and miR-142-3p was identified by dual luciferase reporter gene assay. MiR-142-3p was up-regulated in RA synovial tissues and RA-HFLSs. TNF-α activated the aggressive phenotypes of RA-HFLSs, including enhanced proliferation, migration, invasion, and inflammation, and inhibited apoptosis. miR-142-3p inhibitor significantly decreased the cell viability, the number of cell clones, the migration rate, the number of invasive cells, the contents and expression of IL-6 and MMP-3, and increased the apoptosis rate and the expressions of Bax and Bad, and decreased Bcl-2 expression of TNF-α-treated RA-HFLSs. MiR-142-3p inhibitor significantly reversed TNF-α-induced up-regulation of IRAK1, TLR4, and p-NF-κB p65 in TNF-α-treated RA-HFLSs. Besides, IRAK1 was a target of miR-142-3p. The down-regulation of miR-142-3p inhibited the aggressive phenotypes of RA-HFLSs through inhibiting NF-κB signaling.

Introduction

Rheumatoid arthritis (RA) is a common autoimmune disease that affects 0.5–1% of the population worldwide [1]. RA is characterized by chronic inflammation in synovial tissues, and accompanied with the symptoms of pain, swelling, and stiffness of the joints [2]. Since RA contributes the destruction of cartilage and bone, RA is considered as one of the most common causes of disability [3]. In clinic practice, the therapeutic strategies for RA mainly focus on the control of pain and inflammation, as well as the protection of joint damage [4]. With the increasing revelation of the molecular mechanisms involved in the pathogenesis of RA, molecular targeting therapy has become a promising therapeutic strategy for RA.
Tumor necrosis factor α (TNF-α) is a proinflammatory cytokine that plays a key role in the pathogenesis of RA [5]. Since activated TNF-α is closely associated with the inflammation of synovial tissues, anti-TNF-α has become a promising therapeutic target for RA [6]. Until now, drugs targeting TNF-α have been widely applied in the treatment of RA, such as adalimumab, etanercept and infliximab [7,8]. However, the long-term application of TNF-α antagonists may be accompanied with the risk of infection and malignancy [9,10]. Therefore, novel therapeutic strategies for RA with high efficiency and safety are urgently needed.

MicroRNAs (miRs) are a family of small non-coding RNAs that involved in the occurrence and development of RA [11]. Previous studies have been proved that some miRs are up-regulated in RA, such as miR-146 [12], −155 [13], −203 [14], −221 [15], and −126 [16], and some are down-regulated, such as miR-34a [17], −124a [18], −22 [19], and −188-5p [20]. These miRs exert diverse regulatory roles in the aggressive phenotypes of RA human fibroblast-like synoviocytes (RA-HFLSs). For examples, miR-221 inhibitor inhibits the migration and invasion, and promotes the apoptosis of RA-HFLSs [15]. Lentivirus-miR-126 promotes the proliferation and inhibits the apoptosis of RA-HFLSs [16]. The precursor miR-124a suppresses the proliferation of RA-HFLSs by arresting the cell cycle at the G1 phase [21], and miR-188-5p mimic inhibits the migration of RA-HFLSs [20]. miR-142-3p is an important miR that involved in the regulation of inflammation [22,23]. It has been reported that miR-142-3p mimic alleviates bleomycin-induced apoptosis and overproduction of interleukin (IL)-1 and TNF-α in MLE-12 cells [22]. MiR-142-3p was down-regulated in the articular cartilage tissues of osteoarthritis (OA) mice, and the overexpression of miR-142-3p inhibits lipopolysaccharide (LSP)-induced apoptosis and the production of IL-1, IL-6, and TNF-α [24]. However, the specific regulatory roles of miR-142-3p on RA are still unclear.

In the present study, the expression of miR-142-3p was detected in both RA synovial tissues and RA-HFLSs. The regulatory effects of miR-142-3p on the aggressive phenotypes of RA-HFLSs, including the proliferation, apoptosis, migration, invasion, and inflammation were evaluated. In addition, the potential regulatory mechanisms of miR-142-3p related with nuclear factor-κB (NF-κB) signaling were further analyzed. Our findings may not only provide a novel therapeutic target for RA, but also reveal new insights into the underlying mechanisms of RA.

Methods

Patients

A total of ten RA patients (six males and four females, 52 ± 4 years old) were screened from our hospital between February 2017 and October 2017. During the same period, ten OA patients (three males and seven females, 52 ± 5 years old) were randomly screened. Both OA and RA were diagnosed according to the criteria established by the American College of Rheumatology. The present study was approved by the local Institutional Review Board, and informed consents were obtained from all subjects.

Isolation and culturing of HFLSs

RA-HFLSs and OA-HFLSs were isolated from synovial tissues of RA and OA patients, respectively. Simply, synovial tissues were washed with phosphate buffer saline (PBS), cut into fragments, and digested with 0.1% Type-I collagenase (Sigma, St. Louis, MO, U.S.A.) for 4 h at 37°C. Followed by 5 min of centrifugation at 1000 rpm/min, HFLSs were resuspended in High-glucose Dulbecco’s modified eagle medium (H-DMEM) (Hyclone, Thermo Fisher Scientific, Waltham, MA, U.S.A.) containing 10% fetal bovine serum (FBS). Normal HFLSs, and HEK-293T cells (human renal epithelial cell line) were purchased from The Cell Bank of Chinese Academy of Sciences (Shanghai, China), and maintained in H-DMEM containing 10% FBS. All cells were cultured in a humidified incubator at 37°C with 5% CO2. The medium was refreshed every 2 days, and cells were passaged until 80–90% confluence. Logarithmic growth phase cells (third to eighth generation) were used for treatments.

Cell transfection and treatments

MiR-142-3p inhibitor and miR-142-3p inhibitor negative control (INC) were purchased from Guangzhou Ruibo Biotechnology Co., Ltd. (Guangzhou, China). RA-HFLSs were seeded in 6-well plates at a density of 6×10^5 cell/well, and transfected with miR-142-3p inhibitor or INC using lipofectamine 2000 (Thermo Fisher Scientific). After 24 h of transfection, the transfected-HFLSs were treated with 10 μg/l TNF-α for 24 h. RA-HFLSs were randomly divided into four groups, including Mock (RA-HFLSs without treatment), TNF-α (RA-HFLSs treated with TNF-α), INC + TNF-α (RA-HFLSs transfected with INC and treated with TNF-α), and Inhibitor + TNF-α (RA-HFLSs transfected with miR-142-3p inhibitor and treated with TNF-α).
Table 1 The sequences of specific primers used in qRT-PCR

| Primers | Forward  | Reverse  |
|---------|----------|----------|
| miR-142-3p | 5′-GGGTGTAGTGTTTCCTACT-3′ | 5′-CAGTGGCGTGTCGTGGAGT-3′ |
| U6      | 5′-TGCGGGTGCTCCGCTTCGGCAGC-3′ | 5′-CAGTGACAGGTCGCAAGGT-3′ |
| IL-6    | 5′-TGAGCATGGCGGATTACTC-3′ | 5′-CAGTGGAGGCTCAGTCATCC-3′ |
| Bcl-2   | 5′-GGTGGGGTCATGTGTGTGG-3′ | 5′-CGGTTCAGGTACTCAGTCATCC-3′ |
| Bax     | 5′-GGTGGGGTCATGTGTGTGG-3′ | 5′-CGGTTCAGGTACTCAGTCATCC-3′ |
| Bad     | 5′-GGTGGGGTCATGTGTGTGG-3′ | 5′-CGGTTCAGGTACTCAGTCATCC-3′ |
| MMP-3   | 5′-GGTGGGGTCATGTGTGTGG-3′ | 5′-CGGTTCAGGTACTCAGTCATCC-3′ |
| IRAK1   | 5′-GGTGGGGTCATGTGTGTGG-3′ | 5′-CGGTTCAGGTACTCAGTCATCC-3′ |
| GAPDH   | 5′-GGTGGGGTCATGTGTGTGG-3′ | 5′-CGGTTCAGGTACTCAGTCATCC-3′ |

Quantitative real-time PCR

Total RNA was extracted from HFLSs using TRIzol agent (Thermo Fisher Scientific), and cDNA was reverse-transcribed using PrimeScript RT reagent Kit (TaKaRa, Japan) in accordance with manufacturer’s instructions. Quantitative real-time PCR (qRT-PCR) was performed on ABI 7500 (Applied Biosystems, Foster City, CA, U.S.A.) using specific primers (Table 1). The PCR program included 95°C for 3 min, 40 cycles at 95°C for 15 s, 60°C for 20 s, and 72°C for 20 s. U6 and GAPDH were used as internal controls. The relative expression of target genes were calculated according to the $2^{-\Delta\Delta C_{t}}$ method [25].

Northern analysis of miRNAs

Northern analysis of miRNAs was performed as previously described [26]. Briefly, total 10 μg RNA was separated on 15% polyacrylamide–urea gels, transferred onto a Zeta-probe membrane (BioRad, Hercules, CA, U.S.A.), and crosslinked by ultraviolet irradiation. The blots were pre-hybridized, and hybridized with specific probes, γ-32P end-labeled miR-142-3p probes or U6 at 37°C for 16 h.

MTT assay

MTT was performed to detect the viability of RA-HFLSs. Simply, 200 μl RA-HFLSs were seeded in 96-well plates at a density of 6×10³ cells/well, and then incubated with 20 μg MTT (Sigma) for 4 h. After removing the medium, 150 μl DMSO was added into each well. Optical density (OD) at 495 nm was detected by a Microplate Reader ( Molecular Devices, Sunnyvale, CA, U.S.A.).

Colony formation assay

Colony formation assay was performed to detect the colony-forming ability of RA-HFLSs. Simply, RA-HFLSs were seeded in 6-well plates at a density of 500 cells/well, and cultured for 14 days. After removing the medium, the colonies were fixed in methanol for 15 min and stained with crystal violet for 15 min. The stained colonies were observed under microscope (Olympus, Tokyo, Japan), and counted by using the software of ImageJ version 1.48V (National Institutes of Health, Bethesda, MD, U.S.A.).

TUNEL assay

TUNEL assay was performed to detect the apoptosis of RA-HFLSs. Simply, RA-HFLSs were fixed in 4% paraformaldehyde for 1 h, permeabilized with 0.1% TritonX-100/0.1% sodium citrate for 2 min, and blocked with 3% H2O2 for 10 min. Then cells were stained with TUNEL (Roche, Basel, Switzerland) in accordance with manufacturer’s instructions. Positive-stained cells were observed under microscope (Olympus), and counted in five randomly selected fields (×100).

Wound healing assay

Wound healing assay was performed to detect the migratory ability of RA-HFLSs. Simply, RA-HFLSs were seeded in 6-well plates at a density of 5×10⁵ cells/well. When reaching 90% confluence, a wound track was scored in each well with a pipette tip. The cell debris were removed by washing with PBS. After 48 h of culturing, the migrated cells were observed under microscope (Olympus), and the migratory distance was measured.
Transwell assay
Transwell assay was performed to detect the invasive ability of RA-HFLSs by using transwell chambers (BD, Franklin Lakes, NJ, U.S.A.). Simply, 100 μl cells were seeded in the upper chamber (pre-coated with Matrigel) at a density 1×10^5 cells/well. The lower chamber is filled with 500 μl DMEM containing 10% FBS. Followed by 48 h of incubation at 37°C, cells on the upper chamber were removed with cotton swabs. Cells on the lower chamber were washed with PBS, fixed in 4% paraformaldehyde for 15 min, and stained with 0.1% crystal violet for 10 min. Positive-stained cells were observed under microscope (Olympus), and counted in five randomly selected fields (×100).

Western blot
RA-HFLSs were lysed in RIPA Lysis buffer (Beyotime, Shanghai, China). Total proteins were separated by sodium dodecyl sulfate/polyacrylamide gel electrophoresis on 10% polyacrylamide gels, and transferred to polyvinylidene-fluoride membrane (Millipore, Billerica, MA, U.S.A.). Then the membrane was blocked with 0.5% skim milk in Tris-buffered saline Tween (TBST) for 1 h, and incubated with specific primary antibodies (rabbit anti-human; anti-IRAK1, #ab245342; anti-TLR4, #ab13556; anti-p-NF-κB p65, #ab86299; anti-Bcl-2, #ab196495; anti-Bax, #ab32503; Bad, #ab32445; anti-GAPDH, #ab9485; 1:1000, Abcam, Cambridge, England; NF-κB p65, 1:1000, #3033, Cell Signal, U.S.A.) overnight at 4°C. Followed by three times of washing with TBST, the membrane was incubated with horseradish peroxidase (HRP)-conjugated secondary antibody (goat anti-rabbit; 1: 5000, Sigma) for 1 h at 37°C. The protein brands were visualized using HRP color development kit (Thermo Fisher Scientific).

Enzyme-linked immunosorbent assay
The contents of IL-6, and matrix metalloproteinase 3 (MMP-3) were detected in RA-HFLSs by using enzyme-linked immunosorbent assay (ELISA) kits (eBioscience, Thermo Fisher Scientific) in accordance with manufacturer’s instructions. The OD at 450/550 nm was measured by a Microplate Reader (Molecular Devices).

Dual luciferase reporter gene assay
Dual luciferase reporter gene (DLR) assay was performed to identify the interaction between IL-1 receptor-associated kinase 1 (IRAK1) and miR-142-3p. Simply, HEK-293T cells were co-transfected with PsiCHECK-2 luciferase plasmids (Promega, Madison, WI, U.S.A.) carrying IRAK1-wild-type (PSMD11-WT)/IRAK1-mutant (PSMD11-MT) and miR-142-3p mimics/miR-142-3p mimics negative control (NC) (Ruibo). After 48 h of transfection, the fluorescence was visualized using a Dual Luciferase Reporter Assay Kit (Promega) according to the manufacturer’s instructions. The fluorescence intensity was detected by a Microplate Reader (Molecular Devices).

Statistical analyses
All data were expressed as mean ± standard deviation. Statistical analysis was performed by SPSS version 18.0 (SPSS Inc., Chicago, IL, U.S.A.). Comparison between different groups was determined by t test (two groups) or one-way ANOVA (more than two groups). A P value less than 0.05 represented significantly different.

Results

MiR-142-3p was up-regulated in RA
The expression of miR-142-3p was detected in both RA tissues and RA-HFLSs. qRT-PCR showed that the expression of miR-142-3p in synovial tissues was significantly higher in RA patients than in OA patients, and was significantly higher in RA patients at stage IV than in those at stage III (P<0.05) (Figure 1A,B). RA- and OA-HFLSs were isolated from synovial tissues of RA and OA patients, respectively. The expression of miR-142-3p was significantly higher in RA-HFLSs than in OA-HFLSs (P<0.05). No significant difference on the expression of miR-142-3p was observed between OA-HFLSs and HFLSs (normal control) (Figure 1C). Additionally, Northern blot analysis showed that miR-142-3p was significantly up-regulated in RA patients compared with OA patients (Figure 1D). Similarly, expression of miR-142-3p in RA-HFLSs was higher than that in OA-HFLSs and TFLSs (Figure 1E).

Down-regulation of miR-142-3p inhibited TNF-α-induced proliferation of RA-HFLSs
The viability of RA-HFLSs was detected by MTT assay. As shown in Figure 2A, the viability (OD₄₉₅ value) of RA-HFLSs was significantly increased with increasing concentrations of TNF-α in a dose-dependent manner until a peak at 10 μg/l (P<0.05). The results of Figure 2B showed the mRNA expression of miR-142-3p in inhibitor
Figure 1. The expression of miR-142-3p detected by qRT-PCR

(A) Relative miR-142-3p mRNA expression in synovial tissues of OA and RA patients (n=10); (B) Relative miR-142-3p mRNA expression in synovial tissues of OA patients at stage III and IV (n=5); (C) Relative miR-142-3p mRNA expression in OA human fibroblast-like synoviocytes (OA-HFLSs), RA-HFLSs, and normal HFLSs; (D) Northern blot analysis of miR-142-3p in synovial tissues of OA and RA patients (n=10); (E) Northern blot analysis of miR-142-3p in OA-HFLSs, RA-HFLSs and normal HFLSs. *, P<0.05 versus OA (A) RAIII (B) or HFLS and OA-HFLS (C).

Down-regulation of miR-142-3p promoted TNF-α-induced apoptosis of RA-HFLSs

The apoptosis of RA-HFLSs was detected by TUNEL staining. As shown in Figure 3A,B, the apoptosis rate of RA-HFLSs was significantly lower in TNF-α group than in Mock group (P<0.05). The transfection of miR-142-3p inhibitor significantly increased the apoptosis rate of TNF-α-treated RA-HFLSs (P<0.05) (Figure 3A,B). In addition, the expression of B-cell lymphoma-2 (Bcl-2), an apoptotic marker was significantly higher in TNF-α group than in Mock group at both the mRNA and protein level (P<0.05). On the contrary, the expressions of Bax and Bad in TNF-α group were remarkably lower than those in Mock group (P<0.05). The transfection of miR-142-3p inhibitor significantly down-regulated Bcl-2 and up-regulated Bax and Bad in TNF-α-treated RA-HFLSs (P<0.05) (Figure 3C,D). The apoptosis rate and the expressions of Bcl-2, Bax, and Bad were not significantly influenced by the transfection of INC (Figure 3A–D).
Figure 2. The proliferation of RA-HFLSs

(A) The viability (OD495 value) of RA-HFLSs under the treatment of different concentrations of TNF-α (n=5); (B) The mRNA expression of miR-142-3p was detected by quantitative real-time PCR; (C) The viability of RA-HFLSs under the treatment of 10 μg/l TNF-α for different times (n=5). (D) The number of cell clones formed by TNF-α-treated RA-HFLSs (n=5). Mock, RA-HFLSs without treatment; TNF-α, RA-HFLSs treated with TNF-α; INC + TNF-α, RA-HFLSs transfected with miR-142-3p INC and treated with TNF-α; Inhibitor + TNF-α, RA-HFLSs transfected with miR-142-3p inhibitor and treated with TNF-α. a, b, a n c, P < 0.05 versus 0, 5, 10, 20 mg/l TNF-α, respectively (A). *, P < 0.05 versus Mock and INC (B). *, P < 0.05 versus Mock; #, P < 0.05 versus TNF-α and INC + TNF-α (B and C).

Down-regulation of miR-142-3p inhibited TNF-α-induced migration and invasion of RA-HFLSs

The migration and invasion of RA-HFLSs was detected by wound healing assay and transwell assay, respectively. As shown in Figure 4A, the migration rate of RA-HFLSs was significantly higher in TNF-α group than in Mock group (P < 0.05). The transfection of miR-142-3p inhibitor significantly decreased the migration rate of TNF-α-treated RA-HFLSs (P < 0.05). The migration of RA-HFLSs was not significantly influenced by the transfection of INC (Figure 4A). Consistent results with the migration rate were observed on the number of invasive RA-HFLSs (Figure 4B).
Figure 3. The apoptosis of RA-HFLSs
(A) TUNEL staining of RA-HFLSs under microscope (×100); (B) The apoptosis rate of RA-HFLSs (n=5); (C) The relative mRNA expression of Bcl-2, Bax and Bad. (D) The relative protein expression of Bcl-2, Bax and Bad. Mock, RA-HFLSs without treatment; TNF-α, RA-HFLSs treated with TNF-α; INC + TNF-α, RA-HFLSs transfected with miR-142-3p INC and treated with TNF-α; Inhibitor + TNF-α, RA-HFLSs transfected with miR-142-3p inhibitor and treated with TNF-α. *, P<0.05 versus Mock; #, P<0.05 versus TNF-α and INC + TNF-α.

Figure 4. The migration and invasion of RA-HFLSs
(A) The migration rate detected by wound healing assay (n=5); (B) The number of invasive cells detected by transwell assay (n=5). Mock, RA-HFLSs without treatment; TNF-α, RA-HFLSs treated with TNF-α; INC + TNF-α, RA-HFLSs transfected with miR-142-3p INC and treated with TNF-α; Inhibitor + TNF-α, RA-HFLSs transfected with miR-142-3p inhibitor and treated with TNF-α. *, P<0.05 versus Mock; #, P<0.05 versus TNF-α and INC + TNF-α.

Down-regulation of miR-142-3p inhibited TNF-α-induced inflammation of RA-HFLSs
The inflammation of RA-HFLSs was evaluated by the levels of IL-6 and MMP-3. As shown in Figure 5A,B, the con-
Figure 5. The levels of inflammatory factors in RA-HFLSs

(A) IL-6 content; (B) MMP-3 content; (C) Relative IL-6 mRNA expression detected by qRT-PCR; (D) Relative MMP-3 mRNA expression detected by qRT-PCR. Mock, RA-HFLSs without treatment; TNF-α, RA-HFLSs treated with TNF-α; INC + TNF-α, RA-HFLSs transfected with miR-142-3p INC and treated with TNF-α; Inhibitor + TNF-α, RA-HFLSs transfected with miR-142-3p inhibitor and treated with TNF-α. *P < 0.05 versus Mock; #P < 0.05 versus TNF-α and INC + TNF-α.

Contents of IL-6 and MMP-3 were significantly higher in TNF-α group than in Mock group (P < 0.05). The transfection of miR-142-3p inhibitor significantly decreased the contents of IL-6 and MMP-3 in TNF-α-treated RA-HFLSs (P < 0.05). The contents of IL-6 and MMP-3 were not significantly influenced by the transfection of INC (Figure 5A, B). Consistent results with the contents of IL-6 and MMP-3 were observed on the expression of IL-6 and MMP-3 at the mRNA level (Figure 5C, D).

Down-regulation of miR-142-3p inhibited TNF-α-induced activation of NF-κB in RA-HFLSs

In order to reveal the regulatory mechanisms of miR-142-3p relating with NF-κB signaling, the expression of IRAK1, Toll-like receptor 4 (TLR4), NF-κB p65 and phosphorylated NF-κB p65 (p-NF-κB p65) were detected in RA-HFLSs. As shown in Figure 6, the expression of IRAK1, TLR4, and p-NF-κB p65 in RA-HFLSs were significantly higher in TNF-α group than in Mock group (P < 0.05). The transfection of miR-142-3p inhibitor significantly decreased the expression of IRAK1, TLR4, and p-NF-κB p65 in TNF-α-treated RA-HFLSs (P < 0.05). The expression of IRAK1, TLR4, and p-NF-κB p65 were not significantly influenced by the transfection of INC. In addition, NF-κB p65 expression was not statistically significant between different groups (Figure 6).
Figure 6. The expression of IRAK1, TLR4, NF-κB p65, and p-NF-κB p65 in RA-HFLSs detected by Western blot
Mock, RA-HFLSs without treatment; TNF-α, RA-HFLSs treated with TNF-α; INC + TNF-α, RA-HFLSs transfected with miR-142-3p INC and treated with TNF-α; Inhibitor + TNF-α, RA-HFLSs transfected with miR-142-3p inhibitor and treated with TNF-α. *, P < 0.05 versus Mock; #, P < 0.05 versus TNF-α and INC + TNF-α.

IRAK1 was a target of miR-142-3p
Since the miR-142-3p inhibitor significantly down-regulated IRAK1 in TNF-α-treated RA-HFLSs, the specific interaction between IRAK1 and miR-142-3p was further analyzed. As shown in Figure 7A, a binding site of miR-142-3p was predicted at 3′-UTR of IRAK1 by an online target gene prediction software (Target Scan) (Figure 7A). In addition, DLR assay showed that the fluorescence intensity was significantly lower in HEK-293T cells co-transfected with IRAK1-WT + miR-142-3p mimics than those co-transfected with IRAK1-MT + miR-142-3p mimics, IRAK1-MT + NC, and COL1A1-WT + NC (P < 0.05) (Figure 7B).

Discussion
HFLSs are key effector cells in RA, which exhibit aggressive phenotypes, such as enhanced proliferation and migration, and the overproduction of inflammatory cytokines and chemokines [27,28]. TNF-α is a proinflammatory cytokine that plays a key regulatory role in the aggressive phenotypes of RA-HFLSs. It has been reported that TNF-α...
promotes the proliferation, migration, invasion, and MMPs expression in RA-HFLSs [29]. TNF-α induces the proliferation of RA-HFLSs, and the production of IL-6 and IL-1β [30]. In the present study, we found that TNF-α-treated RA-HFLSs exhibited significantly increased cell viability, number of cell clones, migration rate, number of invasive cells, expression of Bcl-2, and levels of IL-6 and MMP-3, as well as decreased apoptosis rate. Our findings are just consistent with pervious studies, and further illustrate that TNF-α activates the aggressive phenotypes of RA-HFLSs.

MiR-142-3p is a specific miR that plays a dual role in tumorigenesis. miR-142-3p not only acts as a tumor suppressor in osteosarcoma [31], gastric cancer [32], colon cancer [33], and non-small-cell lung cancer [34], but also acts as a tumor promoter in pediatric brain tumor [35], renal cell carcinoma [36], and colorectal cancer [37]. Over the past decade, non-coding RNAs including miRNAs and lncRNA gradually become important regulators of inflammation [38]. Until now, the knowledge on roles of miR-142-3p on RA are still limited. In the present study, we found that the expression of miR-142-3p was significantly higher in synovial tissues and RA-HFLSs of RA patients than those of OA patients. These results are consistent with pervious studies on miR-146 [12], -155 [13], -203 [14], -221 [15], and -126 [16], and illustrate that miR-142-3p is up-regulated in RA. In addition, we also found that the expression of miR-142-3p in synovial tissues was significantly higher in RA patients at stage IV than in those at stage III. This result indicates that miR-142-3p expression may be positively associated with the severity of RA. A pervious study indicates that circulating peripheral blood miRs, including miR-16, -21, -24, -26a, -125a-5p, -125b, -126-3p, -223, and -451 are promising non-invasive biomarkers for the detection of RA [39]. We suspect that miR-142-3p may also be used as a biomarker for the diagnosis of RA.

The specific regulatory effects of miR-142-3p on the aggressive phenotypes of RA-HFLSs were further evaluated in the present study. We found that the transfection of miR-142-3p inhibitor significantly decreased the cell viability, the number of cell clones, the migration rate, the number of invasive cells, and the expression of Bcl-2 expression, and increased the expressions of Bax and Bad, and the apoptosis rate of TNF-α-treated RA-HFLSs. A pervious study has proved that the down-regulation of miR-221 inhibits the migration and invasion, and promotes the apoptosis of HFLSs [15]. Our findings are just consistent with miR-221, and illustrate that the down-regulation of miR-142-3p reverses the promoting effects of TNF-α on the proliferation, migration, and invasion of RA-HFLSs. In addition, evidences have proved that miR-142-3p is involved in the regulation of inflammatory process. For examples, miR-142-3p overexpression inhibits LPS-induced production of IL-1, IL-6, and TNF-α in articular cartilage tissues of OA mice [24]. MiR-142-3p overexpression alleviates bleomycin-induced production of IL-1 and TNF-α in MLE-12 cells [22]. In the present study, we found that the transfection of miR-142-3p inhibitor significantly decreased the contents and the expression of IL-6 and MMP-3 in TNF-α-treated RA-HFLSs. These results indicate that the down-regulation of miR-142-3p inhibits TNF-α-induced inflammation of RA-HFLSs. However, our findings are inconsistent with previous studies. Similar with the dual roles of miR-142-3p in tumorigenesis, we suspect that miR-142-3p may exert different regulatory roles on inflammation in different diseases. To sum up, the down-regulation of miR-142-3p may contribute to the amelioration of RA via relieving the aggressive phenotypes of RA-HFLSs, including the enhanced proliferation, migration, invasion, and inflammation, as well as inhibited apoptosis.

Since RA is a chronic inflammatory disease of the synovial joints, activated NF-κB is always detected in synovial tissues of RA [40]. In the present study, we found that TNF-α significantly up-regulated IRAK1, TLR4, and p-NF-κB p65 in RA-HFLSs. These results illustrate that TNF-α induces the activation of NF-κB signaling in RA-HFLSs. In RA-HFLSs, TNF-α stimulation can result in phosphorylation of NF-κB and activation of NF-κB, and then induce the expression of target genes involved in proinflammation, cell cycle, and anti-apoptosis [41]. TNF-α-induced activation of NF-κB signaling contributes to the aggressive phenotypes of RA-HFLSs. NF-κB is a common nuclear transcription factor appeared in osteoblasts. Studies have found that Runx [42], NF-κB signaling [43], and other pathways play important role in osteogenesis differentiation and activity. Cross talks between these pathways or together they regulate osteoblast activity. Disruption of Runx1 and Runx3 could result in bone marrow failure [44], and Runx3 deficiency leads to myeloproliferative disorder [45]. Changes in NF-κB pathway could regulate variations in osteogenesis activity. In the present study, the regulatory mechanisms of miR-142-3p relating with NF-κB signaling were further evaluated. We found that transfection of miR-142-3p inhibitor significantly down-regulated IRAK1, TLR4, and p-NF-κB p65 in TNF-α-treated RA-HFLSs. These results illustrate that the down-regulation of miR-142-3p inhibits TNF-α-induced activation of NF-κB signaling in RA-HFLSs. We suspect that the down-regulation of miR-142-3p may relieve the aggressive phenotypes of RA-HFLSs through inhibiting NF-κB signaling. Besides, our further assays showed that IRAK1 was a target of miR-142-3p. Since IRAK1 is partially responsible for IL1-induced activation of NF-κB signaling [46], the down-regulation of miR-142-3p may inhibit NF-κB signaling by targeting IRAK1.

In conclusion, miR-142-3p was up-regulated in RA synovial tissues and RA-HFLSs. The down-regulation of miR-142-3p significantly relieved TNF-α-induced aggressive phenotypes of RA-HFLSs, including enhanced proliferation, migration, invasion, and inflammation, as well as inhibited apoptosis. In addition, the down-regulation of
miR-142-3p inhibited NF-κB signaling by targeting IRAK1, thereby contributing to the remission of TNF-α-induced aggressive phenotypes of RA-HFLSs. Down-regulation of miR-142-3p may be used as a promising therapeutic target for RA.

Ethics approval and consent to participate
The present study was conducted after obtaining approval of The First Affiliated Hospital of The Fourth Military Medical University’s ethical committee. The research has been carried out in accordance with the World Medical Association Declaration of Helsinki, and that all subjects have been provided written informed consent.

Competing Interests
The authors declare that there are no competing interests associated with the manuscript.

Funding
The authors declare that there are no sources of funding to be acknowledged.

Author Contribution
Jianhong Qiang: conception and design and analysis of data. Jianhong Qiang and Tingting Lv: drafting the article. Zhenbiao Wu and Xichao Yang: revising the article critically for important intellectual content. All authors read and approved the final manuscript.

Abbreviations
ANOVA, analysis of variance; Bcl-2, B-cell lymphoma-2; DLR, dual luciferase reporter gene; DMSO, dimethyl sulfoxide; FBS, fetal bovine serum; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; H-DMEM, high-glucose Dulbecco’s modified Eagle medium; HEK, human embryonic kidney; HRP, horseradish peroxidase; IL, interleukin; ING, inhibitory negative control; IRAK1, IL-1 receptor-associated kinase 1; MMP-3, matrix metalloproteinase 3; MTT, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide; NC, negative control; NF-κB, nuclear factor-κB; OA, osteoarthritis; OA-HFLS, osteoarthritis human fibroblast-like synoviocyte; OD, optical density; PBS, phosphate buffer saline; p-NF-κB p65, phosphorylated NF-κB p65; qRT-PCR, quantitative real-time PCR; RA, rheumatoid arthritis; RA-HFLS, rheumatoid arthritis human fibroblast-like synoviocyte; TBST, tris-buffered saline Tween; TLR4, toll-like receptor 4; TNF-α, tumor necrosis factor α; TUNEL, terminal dextranucleotidyl transferase-mediated dUTP nick end labeling.

References
1 Smolen, J.S., Aletaha, D. and McInnes, I.B. (2016) Rheumatoid arthritis. Lancet 388, 2023–2038, https://doi.org/10.1016/S0140-6736(16)30173-8
2 Shrivastava, A.K. and Pandey, A. (2013) Inflammation and rheumatoid arthritis. J. Physiol. Biochem. 69, 335–347, https://doi.org/10.1007/s13105-012-0216-5
3 Naqvi, A.A. et al. (2017) Development of evidence-based disease education literature for pakistani rheumatoid arthritis patients. Diseases 5, pii: E27, https://doi.org/10.3390/diseases5040027
4 Burmester, G.R. and Pope, J.E. (2017) Novel treatment strategies in rheumatoid arthritis. Lancet 389, 2338–2348, https://doi.org/10.1016/S0140-6736(17)31491-5
5 Arend, W.P. and Dayer, J.M. (2014) Inhibition of the production and effects of interleukins-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum. 38, 151–160, https://doi.org/10.1002/art.1780380202
6 Toussirot, E. and Wendling, D. (2007) The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview. Expert Opin. Pharmacother. 8, 2089–2107, https://doi.org/10.1517/14656566.8.13.2089
7 C, Y-F. et al. (2006) A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol. Assess. (Rocky) 10, 1–229
8 Dong, J.R. et al. (2012) Development of TNF-alpha inhibitor drugs in treatment of rheumatoid arthritis. In Int. Conf. Biomed. Eng. Biotechnol. 149–152
9 Keystone, E.C. (2011) Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data. J. Rheumatol. 38, 1552–1562, https://doi.org/10.3899/jrheum.1000995
10 Meul, G. et al. (2012) Cancer risk of anti-TNF-α inhibitor drugs in patients with rheumatoid arthritis: a meta-analysis of published results. PLoS ONE 7, e48991, https://doi.org/10.1371/journal.pone.0048991
11 Furer, V. et al. (2010) The role of microRNA in rheumatoid arthritis and other autoimmune diseases. Clin. Immunol. 136, 1–15, https://doi.org/10.1016/j.clim.2010.02.005
12 Tomoyuki, N. et al. (2010) Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum. 58, 1284–1292
13 Joanna, S. et al. (2014) Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum. 58, 1001–1009
14 Joanna, S. et al. (2011) Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation. Arthritis Rheum. 63, 373–381, https://doi.org/10.1002/art.30115

© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
Yang, S. and Yang, Y. (2015) Downregulation of microRNA-221 decreases migration and invasion in fibroblast-like synoviocytes in rheumatoid arthritis. Mol. Med. Rep. 12, 2395, https://doi.org/10.3892/mmr.2015.3642

Gu, Y. et al. (2016) MicroRNA-126 affects rheumatoid arthritis synovial fibroblast proliferation and apoptosis by targeting PIK3R2 and regulating PI3K-AKT signal pathway. Oncotarget 7, 74217–74226, https://doi.org/10.18632/oncotarget.12467

Niederer, F. et al. (2012) Down-regulation of microRNA-34a in rheumatoid arthritis synovial fibroblasts promotes apoptosis resistance. Arthritis Rheum. 64, 1771–1779, https://doi.org/10.1002/art.34334

Nakamachi, Y. et al. MicroRNA-124a is a key regulator of proliferation and monocyte chemoattractant protein 1 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum. 60, 1294–1304

Lin, J. et al. (2014) A novel p35/microRNA-22/Cyr61 axis in synovial cells regulates inflammation in rheumatoid arthritis. Arthritis Rheum. 66, 49–59, https://doi.org/10.1002/art.38142

Ruedel, A. et al. (2015) Expression and function of microRNA-188-5p in activated rheumatoid arthritis synovial fibroblasts. J. Clín. Exp. Pathol. 8, 6607

Guo, F. et al. (2017) microRNA-142-3p inhibits apoptosis and differentiation induced by bleomycin through down-regulation of Cox-2 in MLE-12 cells. Braz. J. Med. Biol. Res. 50, e5974, https://doi.org/10.1590/1419-438720175974

Talebi, F. et al. (2017) MicroRNA-142 regulates inflammation and T cell differentiation in an animal model of multiple sclerosis. J. Neuroinflammation 14, 55, https://doi.org/10.1186/s12974-017-0832-7

Wang, X. et al. (2016) MicroRNA-142-3p inhibits chondrocyte apoptosis and inflammation in osteoarthritis by targeting HMGB1. Inflammation 39, 1718–1728, https://doi.org/10.1007/s10582-016-0406-3

Livak, KJ and Schmittgen, T.D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T))Method. Methods 25, 402–408, https://doi.org/10.1006/meth.2001.1262

Garzon, R. et al. (2008) Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Arthritis Rheum. 55, 1294–1304, https://doi.org/10.1002/art.34334

Yang, S. and Yang, Y. (2015) Downregulation of microRNA-221 decreases migration and invasion in fibroblast-like synoviocytes in rheumatoid arthritis. Mol. Med. Rep. 12, 2395, https://doi.org/10.3892/mmr.2015.3642

Qu, Y. et al. (2016) MicroRNA-142-3p inhibits chondrocyte apoptosis and inflammation in osteoarthritis by targeting HMGB1. Osteoarthr. Cartil. 24, 1235, https://doi.org/10.3892/oci.2015.4021

Lee, Y.Y. et al. (2014) MicroRNA142-3p promotes tumor-initiating and radioresistant properties in malignant pediatric brain tumors. Cell Rep. 8, 6607, https://doi.org/10.1016/j.celrep.2014.06.046

Yang, S. and Yang, Y. (2015) Downregulation of microRNA-221 decreases migration and invasion in fibroblast-like synoviocytes in rheumatoid arthritis. Mol. Med. Rep. 12, 2395, https://doi.org/10.3892/mmr.2015.3642

Reference deleted

Churov, A.V., Oleinik, E.K. and Knip, M. (2015) MicroRNAs in rheumatoid arthritis: altered expression and diagnostic potential. Autoimmun. Rev. 14, 1029–1037, https://doi.org/10.1016/j.autrev.2015.07.005

Roman-Blas, J.A. and Jimenez, S.A. (2006) NF-κB signaling pathways in osteoblasts differentiation in response to mechanical stretch. J. Mol. Med. 91, 989–1000, https://doi.org/10.1002/jmm.1037-x

Xiao, P. and Liu, W.L. (2015) MicroRNA-142-3p functions as a potential tumor suppressor directly targeting HMGB1 in non-small-cell lung carcinoma. J. Cell Biol. 200, 10800

Yang, Y.Q. et al. (2014) MicroRNA-142-3p, a novel target of tumor suppressor menin, inhibits osteosarcoma cell proliferation by down-regulation of FASN. Tumour Biol. 35, 10267–10293, https://doi.org/10.1007/s13277-014-2316-z

Shen, W.W. et al. (2013) MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells. J. Mol. Med. 91, 1884–1894, https://doi.org/10.1007/s00109-013-1037-x

Xiong, G. et al. (2018) MicroRNA-142-3p promotes cellular invasion of colorectal cancer cells by activation of RAC1. Trends Mol. Med. 24, 10800

Chew, C.L. et al. (2018) Noncoding RNAs: master regulators of inflammatory signaling. Trends Mol. Med. 24, 66–84, https://doi.org/10.1016/j.trendsmed.2017.11.003

Churov, A.V., Oleinik, E.K. and Knip, M. (2015) MicroRNAs in rheumatoid arthritis: altered expression and diagnostic potential. Autoimmun. Rev. 14, 1029–1037, https://doi.org/10.1016/j.autrev.2015.07.005

Roman-Blas, J.A. and Jimenez, S.A. (2006) NF-κB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Arthritis Cartilage 14, 839–848, https://doi.org/10.1002/joca.2006.004.008

Loo, G.V. and Beyaert, R. (2011) Negative regulation of NF-κB and its involvement in rheumatoid arthritis. Arthritis Res. Ther. 13, 221–221, https://doi.org/10.1186/ar3324

Hesse, E. et al. (2010) Zfp521 controls bone mass by HDAC3-dependent attenuation of Runx2 activity. J. Cell Biol. 191, 1271–1283, https://doi.org/10.1083/jcb.201009107

Wang, L. et al. (2012) Disruption of Runx1 and Runx3 leads to bone marrow failure and leukemia predisposition due to transcriptional and DNA repair defects. Cell Rep. 8, 767–782, https://doi.org/10.1016/j.celrep.2014.06.046

Wang, C.Q. et al. (2014) Disruption of Runx1 and Runx3 deficiency results in myeloproliferative disorder in aged mice. Blood 122, 566–566, https://doi.org/10.1182/blood-2012-10-460618

© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
Liu, G., Park, Y.J. and Abraham, E. (2008) Interleukin-1 receptor-associated kinase (IRAK)-1-mediated NF-kappaB activation requires cytosolic and nuclear activity. *FASEB J.* 22, 2285–2296, https://doi.org/10.1096/fj.07-101816